Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as a sterile solution for subcutaneous, intravenous, and haemodialysis use. It is employed to prevent and treat venous thromboembolic disorders in patients undergoing surgery, those with established deep vein thrombosis, and individuals receiving haemodialysis.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Innohep, a low molecular weight heparin, is used in clinical settings that require inhibition of clot formation in the venous system. - Prevention of deep vein thrombosis (DVT) in surgical patients: reduces postoperative clot risk. - Treatment of established deep vein thrombosis: facilitates clot resolution and prevents extension. - Prevention of pulmonary embolism: lowers the chance of emboli migrating to the lungs. - Anticoagulation during haemodialysis: maintains circuit patency and prevents clotting.

Adverse reactions to Innohep can range from mild to severe and should be monitored during therapy. Common Side Effects: - Injection site erythema or pain. - Minor bruising or hematoma at the injection site. - Transient increase in liver enzymes. - Nausea or mild gastrointestinal discomfort. Serious or Rare Side Effects: - Major bleeding, including intracranial or gastrointestinal hemorrhage. - Heparin‑induced thrombocytopenia (HIT) with platelet count drop. - Allergic reactions such as urticaria, angioedema, or anaphylaxis.

When prescribing Innohep, clinicians should consider several safety measures to minimize risk. - Renal impairment: adjust dosing and monitor anti‑Xa levels. - Concomitant anticoagulants or antiplatelet agents: increase bleeding risk. - Recent or active major surgery: assess bleeding risk before initiation. - History of heparin‑induced thrombocytopenia: avoid use and consider alternative anticoagulants. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Innohep may interact with other medicines, altering its anticoagulant effect. Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increased bleeding risk. - Potent antiplatelet agents (e.g., clopidogrel, high‑dose aspirin): synergistic anticoagulation leading to severe hemorrhage. Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may prolong bleeding time; monitor for signs of hemorrhage. - Certain antibiotics (e.g., quinolones, macrolides): can affect renal clearance of tinzaparin; observe anti‑Xa activity.